DVAX(DVAX)
DVAX
ANALYST COVERAGE11 analysts
BUY
▲ +87.1%upside to target
L $20.00
Med $29.00consensus
H $32.00Key MetricsTTM
Market Cap$1.82B
Revenue TTM$330.51M
Net Income TTM-$43.40M
Free Cash Flow$80.54M
Gross Margin83.2%
Operating Margin3.2%
Net Margin-13.1%
Return on Equity-8.1%
Return on Assets-4.6%
Debt / Equity0.53
Current Ratio7.62
EPS TTM$-0.37
PRICE
Prev Close
15.50
Open
15.50
Day Range—
52W Range9.20 – 15.73
9.20
15.73
96% of range
VOLUME & SIZE
Avg Volume
3.2M
FUNDAMENTALS
P/E Ratio
-41.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.44
Market-like
TECHNICAL
RSI (14)
90
Overbought
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19
DVAX News
About
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Ryan Spencer
Website
Dong YuSenior Vice President of Research
Robert JanssenChief Medical Officer and Senior Vice President of Clinical Development, Medical & Regulatory Affairs
David F. NovackSenior VP & COO
Donn CasaleSenior Vice President & Chief Commercial Officer
Eric FringsVice President, Site Head & MD for Dynavax GmbH
Jeff CoonSenior Vice President & Chief Human Resources Officer
John SlebirSenior Vice President & General Counsel
Joseph MetzingerVice President & Chief Accounting Officer
Paul CoxVice President of Investor Relations & Corporate Communications
Ryan SpencerChief Executive Officer & Director
Kelly MacDonaldSenior Vice President & Chief Financial Officer
Meg SmithSenior Vice President of Commercial